SCHEMBL6162537

SCHEMBL6162537

Cc1ccccc1-c1cc(C(=O)N2CCCC2CO)c2ccccc2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.66
MEN1 O00255 2/20 0.66
POLB P06746 1/20 0.66
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
HTT P42858 2/20 0.46
ATM Q13315 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
MAPT P10636 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
TACR3 P29371 1/20 0.45
TRPV1 Q8NER1 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6164938 1.00 KMT2A (0.66) KMT2AMEN1POLBKDM4EALDH1A1
SCHEMBL6162527 1.00 KMT2A (0.66) KMT2AMEN1POLBKDM4EALDH1A1
SCHEMBL6165671 0.88 MEN1 (0.49) KMT2AMEN1POLBKDM4EHTT
SCHEMBL6164237 0.88 MEN1 (0.49) KMT2AMEN1POLBKDM4EHTT
SCHEMBL6163315 0.88 MEN1 (0.49) KMT2AMEN1POLBKDM4EHTT
SCHEMBL6163232 0.86 TRPV1 (0.57) POLBKDM4EALDH1A1HPGDCYP1A2
SCHEMBL6161963 0.86 TRPV1 (0.57) POLBKDM4EALDH1A1HPGDCYP1A2
SCHEMBL6166073 0.86 TRPV1 (0.57) POLBKDM4EALDH1A1HPGDCYP1A2
SCHEMBL7236604 0.86 POLB (0.48) KMT2AMEN1POLBKDM4EALDH1A1
SCHEMBL7236610 0.86 POLB (0.48) KMT2AMEN1POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
EP-1337523-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2003-08-27 EP claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 KMT2A 968/4885MEN1 4655/4885POLB 1324/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 KMT2A 968/4885MEN1 4655/4885POLB 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.